About Novavax (NASDAQ:NVAX)
Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NVAX
CUSIP67000210
Phone240-268-2000
Debt
Debt-to-Equity Ratio-3.12%
Current Ratio2.76%
Quick Ratio2.76%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.18 million
Price / Sales20.93
Cash FlowN/A
Price / CashN/A
Book Value($0.31) per share
Price / Book-5.52
Profitability
EPS (Most Recent Fiscal Year)($0.63)
Net Income$-183,760,000.00
Net Margins-589.46%
Return on EquityN/A
Return on Assets-54.30%
Miscellaneous
Employees347
Outstanding Shares381,600,000
Novavax (NASDAQ:NVAX) Frequently Asked Questions
What is Novavax's stock symbol?
Novavax trades on the NASDAQ under the ticker symbol "NVAX."
How were Novavax's earnings last quarter?
Novavax (NASDAQ:NVAX) issued its quarterly earnings results on Wednesday, March, 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. The biopharmaceutical company had revenue of $10.40 million for the quarter, compared to analyst estimates of $7.98 million. Novavax's quarterly revenue was up 92.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.21) EPS. View Novavax's Earnings History.
What price target have analysts set for NVAX?
8 Wall Street analysts have issued 1-year price objectives for Novavax's shares. Their forecasts range from $1.35 to $10.00. On average, they expect Novavax's stock price to reach $3.5125 in the next twelve months. View Analyst Ratings for Novavax.
What are Wall Street analysts saying about Novavax stock?
Here are some recent quotes from research analysts about Novavax stock:
- 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (4/11/2018)
- 2. Cantor Fitzgerald analysts commented, "NanoFlu seasonal flu vaccine could be just what the Dr. ordered. The mismatch of commercially available (egg-production-based) seasonal flu vaccines in the current season underscores the theoretical utility of NVAX’s vaccine production technology. Avoiding influenza virus propagation in eggs could reduce the need for egg adaptation and possible generation of virus particles that do not faithfully resemble the wild type viruses recommended by health organizations for inclusion in flu vaccines. Particularly when prevailing strains are highly pathogenic, e.g., H3N2, having a better matched flu vaccine would seem to be desirable, in our view." (3/15/2018)
Are investors shorting Novavax?
Novavax saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 56,065,847 shares, an increase of 10.1% from the March 15th total of 50,911,520 shares. Based on an average daily trading volume, of 8,148,869 shares, the days-to-cover ratio is currently 6.9 days. Currently, 17.6% of the shares of the company are sold short.
Who are some of Novavax's key competitors?
Some companies that are related to Novavax include Cellectis (CLLS), REGENXBIO (RGNX), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS), Jounce Therapeutics (JNCE), Heska (HSKA), Fate Therapeutics (FATE), EntreMed (CASI), Voyager Therapeutics (VYGR), Mesoblast (MESO), BioCryst Pharmaceuticals (BCRX), PDL Biopharma (PDLI), Vericel (VCEL), Nightstar Therapeutics (NITE) and Agenus (AGEN).
Who are Novavax's key executives?
Novavax's management team includes the folowing people:
- Mr. Stanley Charles Erck, Pres, CEO, Interim CFO, Principal Accounting Officer & Director (Age 70)
- Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 52)
- Mr. John Joseph Trizzino B.S., M.B.A., Sr. VP of Commercial Operations (Age 58)
- Dr. Gregory M. Glenn M.D., Pres of R&D (Age 64)
- Ms. Jill Hoyt, VP of HR & Admin.
Has Novavax been receiving favorable news coverage?
News headlines about NVAX stock have trended positive on Saturday, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Novavax earned a media sentiment score of 0.36 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 45.67 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Novavax?
Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novavax's stock price today?
One share of NVAX stock can currently be purchased for approximately $1.71.
How big of a company is Novavax?
Novavax has a market capitalization of $656.35 million and generates $31.18 million in revenue each year. The biopharmaceutical company earns $-183,760,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Novavax employs 347 workers across the globe.
How can I contact Novavax?
Novavax's mailing address is 20 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]
MarketBeat Community Rating for Novavax (NVAX)
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Novavax (NASDAQ:NVAX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Novavax in the last 12 months. Their average twelve-month price target is $3.5125, suggesting that the stock has a possible upside of 105.41%. The high price target for NVAX is $10.00 and the low price target for NVAX is $1.35. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.38 | 2.25 | 2.29 | 2.25 |
| Ratings Breakdown: | 1 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $3.5125 | $3.3714 | $2.8357 | $3.35 |
| Price Target Upside: | 105.41% upside | 56.08% upside | 33.76% upside | 188.79% upside |
Novavax (NASDAQ:NVAX) Consensus Price Target History
Novavax (NASDAQ:NVAX) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Novavax (NASDAQ:NVAX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Novavax (NASDAQ NVAX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 36.88%
Novavax (NASDAQ NVAX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/31/2018 | Gregory M. Glenn | Insider | Buy | 12,784 | $0.88 | $11,249.92 | |  |
| 11/9/2017 | Stanley C Erck | Insider | Buy | 100,000 | $1.13 | $113,000.00 | 228,279 | |
| 8/31/2017 | James F. Young | Director | Sell | 175,000 | $1.06 | $185,500.00 | | |
| 7/31/2017 | Barclay A. Phillips | CFO | Buy | 2,057 | $0.89 | $1,830.73 | | |
| 5/12/2017 | Michael A Mcmanus Jr | Director | Buy | 20,000 | $0.97 | $19,400.00 | 277,590 | |
| 5/11/2017 | Barclay A Phillips | CFO | Buy | 25,000 | $0.84 | $21,000.00 | 36,612 | |
| 5/11/2017 | Michael A Mcmanus Jr | Director | Buy | 10,000 | $0.84 | $8,400.00 | 257,590 | |
| 5/11/2017 | Stanley C Erck | Insider | Buy | 50,000 | $0.84 | $42,000.00 | 128,279 | |
| 1/31/2017 | Barclay A. Phillips | CFO | Buy | 1,633 | $1.12 | $1,828.96 | | |
| 1/31/2017 | John A. Herrmann III | SVP | Buy | 4,960 | $1.12 | $5,555.20 | | |
| 12/7/2016 | Gregory M Glenn | Insider | Buy | 1,000 | $1.45 | $1,450.00 | 4,427 | |
| 9/22/2016 | John Trizzino | SVP | Buy | 46,000 | $2.17 | $99,820.00 | 85,564 | |
| 9/21/2016 | Gregory M Glenn | Insider | Buy | 1,000 | $1.65 | $1,650.00 | 3,427 | |
| 9/21/2016 | Michael A Mcmanus Jr | Director | Buy | 30,000 | $1.61 | $48,300.00 | 247,590 | |
| 9/20/2016 | Gail Boudreaux | Director | Buy | 100,000 | $1.45 | $145,000.00 | 200,000 | |
| 7/31/2016 | Barclay A. Phillips | CFO | Buy | 422 | $4.29 | $1,810.38 | | |
| 6/6/2016 | Gary C Evans | Director | Sell | 18,998 | $6.50 | $123,487.00 | 321,979 | |
| 5/24/2016 | Gary C Evans | Director | Sell | 50,000 | $5.41 | $270,500.00 | 357,111 | |
| 3/31/2016 | Stanley C Erck | CEO | Sell | 424,778 | $5.19 | $2,204,597.82 | 301,066 | |
| 1/31/2016 | Barclay A. Phillips | CFO | Buy | 405 | $4.38 | $1,773.90 | | |
| 1/31/2016 | Gregory M. Glenn | SVP | Buy | 2,369 | $4.38 | $10,376.22 | | |
| 1/31/2016 | Stanley C. Erck | CEO | Buy | 2,072 | $4.38 | $9,075.36 | | |
| 12/16/2015 | John A Herrmann III | SVP | Sell | 27,945 | $8.64 | $241,444.80 | 40 | |
| 8/24/2015 | Gary C Evans | Director | Sell | 20,000 | $11.24 | $224,800.00 | 340,977 | |
| 8/20/2015 | Barclay A. Phillips | CFO | Sell | 28,656 | $13.06 | $374,247.36 | 9,152 | |
| 8/18/2015 | Gregory M. Glenn | SVP | Sell | 15,000 | $13.52 | $202,800.00 | 1,158 | |
| 8/13/2015 | Gary C Evans | Director | Sell | 6,002 | $13.56 | $81,387.12 | | |
| 6/18/2015 | James F Young | Director | Sell | 50,000 | $9.47 | $473,500.00 | | |
| 6/17/2015 | Rajiv I Modi | Director | Sell | 433,053 | $9.01 | $3,901,807.53 | | |
| 6/11/2015 | Rajiv I Modi | Director | Sell | 11,185 | $9.00 | $100,665.00 | | |
| 6/10/2015 | Rajiv I Modi | Director | Sell | 551,081 | $8.97 | $4,943,196.57 | | |
| 6/9/2015 | Rajiv I Modi | Director | Sell | 47,531 | $8.93 | $424,451.83 | | |
| 6/8/2015 | Rajiv I Modi | Director | Sell | 206,175 | $8.93 | $1,841,142.75 | | |
| 6/4/2015 | Rajiv I Modi | Director | Sell | 504,681 | $8.92 | $4,501,754.52 | | |
| 6/1/2015 | Rajiv I Modi | Director | Sell | 3,500,000 | $8.74 | $30,590,000.00 | | |
| 1/31/2015 | Barclay A Phillips | CFO | Buy | 8,388 | $2.28 | $19,124.64 | | |
| 1/31/2015 | John Trizzino | SVP | Buy | 6,611 | $3.63 | $23,997.93 | | |
| 1/31/2015 | Stanley C Erck | CEO | Buy | 6,122 | $2.28 | $13,958.16 | | |
| 12/16/2014 | Gary C Evans | Director | Sell | 46,701 | $5.72 | $267,129.72 | | |
| 12/12/2014 | Gary C Evans | Director | Sell | 30,000 | $5.77 | $173,100.00 | | |
| 11/20/2014 | Rajiv I Modi | Director | Sell | 518,889 | $5.02 | $2,604,822.78 | | |
| 11/18/2014 | Rajiv I Modi | Director | Sell | 1,481,111 | $5.00 | $7,405,555.00 | | |
| 10/3/2014 | Barclay A Phillips | CFO | Buy | 5,000 | $4.11 | $20,550.00 | | |
| 10/3/2014 | Timothy Jon Hahn | SVP | Buy | 2,500 | $4.05 | $10,125.00 | | |
| 9/26/2014 | Gregory M Glenn | SVP | Sell | 16,809 | $4.16 | $69,925.44 | | |
| 9/25/2014 | Timothy Jon Hahn | SVP | Buy | 9,000 | $4.17 | $37,530.00 | | |
| 7/31/2014 | Barclay A Phillips | CFO | Buy | 8,788 | $2.28 | $20,036.64 | | |
| 7/31/2014 | Russell P Wilson | SVP | Buy | 4,989 | $2.28 | $11,374.92 | | |
| 7/31/2014 | Stanley C Erck | CEO | Buy | 6,788 | $2.28 | $15,476.64 | | |
| 6/17/2014 | John Trizzino | SVP | Buy | 5,500 | $4.51 | $24,805.00 | | |
| 6/16/2014 | John Trizzino | SVP | Buy | 16,500 | $4.51 | $74,415.00 | | |
| 3/25/2014 | Barclay Phillips | CFO | Buy | 5,000 | $4.25 | $21,250.00 | 14,868 | |
| 3/25/2014 | Richard Douglas | Director | Buy | 50,000 | $4.33 | $216,500.00 | 250,000 | |
| 3/25/2014 | Stanley Erck | CEO | Buy | 10,000 | $4.27 | $42,700.00 | 84,868 | |
| 3/21/2014 | Pharmaceuticals Ltd Cadila | major shareholder | Sell | 3,000,000 | $4.95 | $14,850,000.00 | | |
| 1/31/2014 | Barclay Phillips | CFO | Buy | 9,868 | $2.29 | $22,597.72 | 9,868 | |
| 1/31/2014 | Stanley Erck | CEO | Buy | 11,868 | $2.29 | $27,177.72 | 74,868 | |
| 1/31/2014 | Timothy Jon Hahn | SVP | Buy | 9,416 | $2.29 | $21,562.64 | 80,416 | |
| 6/12/2013 | Richard Douglas | Director | Buy | 50,000 | $1.90 | $95,000.00 | | |
| 6/10/2013 | Timothy Jon Hahn | SVP | Buy | 21,000 | $1.88 | $39,480.00 | | |
| 6/7/2013 | Gregory M Glenn | Insider | Buy | 2,000 | $1.92 | $3,840.00 | | |
| 6/6/2013 | James F Young | Director | Buy | 100,000 | $1.91 | $191,000.00 | | |
| 3/11/2013 | James F Young | Director | Buy | 100,000 | $2.03 | $203,000.00 | | |
(Data available from 1/1/2013 forward)
Novavax (NASDAQ NVAX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Q2 2018 Earnings Estimate for Novavax Issued By Piper Jaffray (NVAX)
www.americanbankingnews.com - April 19 at 6:26 AM |
 | Free Research Reports on These Biotech Stocks -- Moleculin Biotech, MyoKardia, Nektar Therapeutics, and Novavax
www.prnewswire.com - April 18 at 8:44 AM |
| Novavax (NVAX) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 17 at 1:54 PM |
| Novavax (NVAX) Price Target Lowered to $2.00 at Piper Jaffray
www.americanbankingnews.com - April 17 at 8:27 AM |
 | Buy Novavax After Its Latest Pullback?
finance.yahoo.com - April 17 at 8:25 AM |
| Novavax Announces Closing of Public Offering
finance.yahoo.com - April 16 at 5:29 PM |
| Piper Jaffray Reiterates "Hold" Rating for Novavax (NVAX)
www.americanbankingnews.com - April 15 at 11:42 PM |
| Novavax (NVAX) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 15 at 11:11 PM |
| Novavax (NVAX) Earns Neutral Rating from Chardan Capital
www.americanbankingnews.com - April 15 at 2:21 PM |
| Novavax (NVAX) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - April 15 at 12:35 PM |
 | Novavax, Inc.
www.streetinsider.com - April 13 at 5:26 PM |
| Today’s Research Reports on Stocks to Watch: Novavax and Pfizer
finance.yahoo.com - April 13 at 8:32 AM |
 | Here's Why Novavax, Inc. Is Sinking
www.fool.com - April 12 at 5:29 PM |
| Here's Why Novavax, Inc. Is Sinking
finance.yahoo.com - April 12 at 5:29 PM |
| Novavax's stock plunges on heavy volume after public offering prices at deep discount
finance.yahoo.com - April 12 at 5:29 PM |
 | Novavax Pulls The Trigger On A Stock Offering: What Now?
seekingalpha.com - April 12 at 8:44 AM |
| Novavax (NVAX) Short Interest Update
www.americanbankingnews.com - April 12 at 1:09 AM |
| Novavax -11.1% on report of 25M-share offering at $1.65
seekingalpha.com - April 11 at 7:28 PM |
| Novavax Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 11 at 5:26 PM |
| Novavax (NVAX) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 11 at 9:21 AM |
| BidaskClub Upgrades Novavax (NVAX) to "Hold"
www.americanbankingnews.com - April 10 at 3:28 PM |
| Novavax (NVAX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 10 at 9:44 AM |
| $8.83 Million in Sales Expected for Novavax (NVAX) This Quarter
www.americanbankingnews.com - April 9 at 4:41 AM |
| UPDATE: JPMorgan Downgrades Novavax (NVAX) to Underweight
www.streetinsider.com - April 8 at 9:05 AM |
| Zacks: Brokerages Expect Novavax (NVAX) Will Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 7 at 1:15 AM |
| Pick 3 Biotech Money-Spinning Bets Amid Market Instability
finance.yahoo.com - April 6 at 5:25 PM |
| Novavax (NVAX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 5 at 9:34 AM |
| Novavax (NVAX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 3:40 PM |
| 3 Top Small-Cap Biotech Stocks for Aggressive Investors
finance.yahoo.com - April 3 at 8:13 AM |
| Novavax (NVAX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 3 at 7:49 AM |
| Novavax's (NVAX) "Buy" Rating Reiterated at B. Riley
www.americanbankingnews.com - April 3 at 7:48 AM |
| Novavax (NVAX) Raised to "Buy" at Citigroup
www.americanbankingnews.com - April 2 at 9:42 PM |
 | Novavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine Congress
www.globenewswire.com - April 2 at 9:14 AM |
| Novavax to Present Clinical Data on RSV F and NanoFlu(TM) Vaccines at World Vaccine Congress
finance.yahoo.com - April 2 at 9:14 AM |
| Seaport Global Securities Weighs in on Novavax's Q1 2018 Earnings (NVAX)
www.americanbankingnews.com - March 30 at 6:52 AM |
| Analysts’ Ratings for Sorrento and Its Peers in March 2018
finance.yahoo.com - March 29 at 5:16 PM |
| What Analysts Recommend for AbbVie and Peers in March 2018
finance.yahoo.com - March 29 at 5:16 PM |
| Seaport Global Securities Upgrades Novavax (NVAX) to Buy
www.americanbankingnews.com - March 29 at 12:12 PM |
| Novavax (NVAX) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 10:58 AM |
| Novavax (NVAX) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 28 at 10:26 AM |
| Forget Merck: Novavax, Inc. Is a Better Vaccine Stock
finance.yahoo.com - March 28 at 8:01 AM |
| Short Interest in Novavax (NVAX) Expands By 4.7%
www.americanbankingnews.com - March 28 at 2:02 AM |
| Novavax (NVAX) PT Set at $10.00 by B. Riley
www.americanbankingnews.com - March 24 at 2:45 PM |
| Ladenburg Thalmann Financial Services Reaffirms "Buy" Rating for Novavax (NVAX)
www.americanbankingnews.com - March 24 at 1:56 PM |
| Novavax (NVAX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 23 at 9:34 PM |
| When Will Novavax Inc (NASDAQ:NVAX) Become Profitable?
finance.yahoo.com - March 23 at 6:07 PM |
| Novavax, Inc. to Post FY2018 Earnings of ($0.83) Per Share, Cantor Fitzgerald Forecasts (NVAX)
www.americanbankingnews.com - March 23 at 10:38 AM |
| Analysts Expect Novavax, Inc. (NVAX) Will Post Quarterly Sales of $9.60 Million
www.americanbankingnews.com - March 23 at 9:36 AM |
| Novavax, Inc. Forecasted to Post FY2019 Earnings of ($0.58) Per Share (NVAX)
www.americanbankingnews.com - March 22 at 3:17 PM |
| Novavax: New RSV Vaccine Timeline Raises Cash Concerns - Seeking Alpha
seekingalpha.com - March 22 at 8:25 AM |
Novavax (NASDAQ:NVAX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Novavax (NASDAQ:NVAX) Income Statement, Balance Sheet and Cash Flow Statement
Novavax (NASDAQ NVAX) Stock Chart for Saturday, April, 21, 2018
Loading chart…
